PYC Therapeutics Limited (ASX:PYC)
1.495
-0.015 (-0.99%)
At close: Feb 5, 2026
PYC Therapeutics Revenue
In the fiscal year ending June 30, 2025, PYC Therapeutics had annual revenue of 23.49M AUD with 6.51% growth. PYC Therapeutics had revenue of 11.66M in the half year ending June 30, 2025, a decrease of -5.49%.
Revenue
23.49M
Revenue Growth
+6.51%
P/S Ratio
37.11
Revenue / Employee
4.70M
Employees
5
Market Cap
871.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 23.49M | 1.44M | 6.51% |
| Jun 30, 2024 | 22.06M | 6.25M | 39.56% |
| Jun 30, 2023 | 15.81M | -236.57K | -1.47% |
| Jun 30, 2022 | 16.04M | 12.97M | 421.83% |
| Jun 30, 2021 | 3.07M | 678.66K | 28.33% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 1.01B |
| Neuren Pharmaceuticals | 218.86M |
| Clinuvel Pharmaceuticals | 95.02M |
| Mesoblast | 26.23M |
| Clarity Pharmaceuticals | 9.46M |
| Orthocell | 7.55M |
| Racura Oncology | 6.04M |
| Dimerix | 5.59M |